Clin­i­cal tri­al brand­ing? Biotechs and phar­mas mi­grate name and iden­ti­ty strate­gies even ear­li­er

Brand­ing is mov­ing more and more down­stream in­to clin­i­cal tri­als. Biotech and phar­ma com­pa­nies are think­ing about drug brand prod­uct names and iden­ti­ties much soon­er in the de­vel­op­ment process, but there’s al­so an­oth­er trend brew­ing in ear­ly mar­ket­ing strate­gies — clin­i­cal tri­al brand­ing.

With drug de­vel­op­ment fo­cus­ing in on more rare dis­eases and small­er pa­tient pop­u­la­tions, bio­phar­mas are fight­ing for mind­share and look­ing for a way to stand out to pa­tients and health­care pro­fes­sion­als. And that’s where Phase II clin­i­cal tri­al brand­ing is start­ing to fire up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER